STOCK TITAN
  1. Home
  2. News
  3. ALC

Alcon Inc. - ALC STOCK NEWS

Welcome to our dedicated news page for Alcon (Ticker: ALC), a resource for investors and traders seeking the latest updates and insights on Alcon.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alcon's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alcon's position in the market.

News
Alcon Publishes Agenda for 2024 Annual General Meeting
Rhea-AI Summary
Alcon (ALC) announces its second in-person Annual General Meeting (AGM) with a proposed dividend of CHF 0.24 cash per share. Shareholders will vote on the Report on Non-Financial Matters, among other agenda items. The AGM will take place on May 8, 2024, with important dates for dividend payment outlined.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
News
Alcon Strengthens Leadership in IOL Innovation with the launch of the Clareon Presbyopia Correcting IOLs in India
Rhea-AI Summary
Alcon launches Clareon Family of intraocular lenses in India, offering exceptional clarity and predictable refractive outcomes. The new IOL material has low levels of haze and nanoglistenings, setting it apart from competitors. The Clareon platform includes PanOptix and Vivity technologies, with high patient satisfaction rates. Alcon aims to revolutionize cataract surgery with innovative IOL technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.02%
Tags
none
-
News
Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone
Rhea-AI Summary
Alcon celebrates surpassing one million implants of AcrySof IQ Vivity and Clareon Vivity extended depth of focus intraocular lenses globally. Vivity, with its patented wavefront-shaping technology, offers excellent outcomes for cataract patients, addressing presbyopia and expanding patient candidacy pool.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
News
Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023
Rhea-AI Summary
Alcon (ALC) reported strong financial results for Q4 2023, with sales of $2.3 billion, up 8% or 10% constant currency, and diluted EPS of $0.86. FY 2023 sales were $9.4 billion, up 8%, and diluted EPS was $1.96. The company projects 6-8% sales growth and 13-16% core diluted EPS growth for FY 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
earnings
-
News
Alcon Canada Launches TOTAL30 Multifocal Contact Lenses for Reusable Lens Patients with Presbyopia
Rhea-AI Summary
Alcon has launched TOTAL30 Multifocal, the first monthly Water Gradient multifocal contact lens that provides excellent visual acuity at all distances, addressing the needs of the growing global multifocal market. The lens helps outsmart digital device dryness and presbyopia, which affects nearly 80% of people aged 45-55. The company aims to offer premium Water Gradient innovation at an accessible price point, with a proven fit success rate of 96%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
none
-
News
Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye
Rhea-AI Summary
Alcon (ALC) announced positive topline results from the two pivotal Phase 3 clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of dry eye disease (DED). In both trials, the primary endpoint of the proportion of subjects with at least a 10-mm increase in unanesthetized Schirmer’s score achieved statistical significance at Day 14 [p<0.0001]. Dry eye affects an estimated 38 million people in the U.S. and less than 10% of diagnosed patients are treated with a prescription product. AR-15512 has the potential to address the limitations of current dry eye prescription options and provide Eye Care Professionals (ECPs) and dry eye sufferers with a new and effective approach to the management of dry eye, a chronic and undertreated disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.54%
Tags
clinical trial
News
Alcon to Present at 2024 Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Alcon (ALC) CEO David Endicott to Present at 2024 J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
conferences
-
News
Alcon Reports Third Quarter 2023 Results
Rhea-AI Summary
Alcon (SIX/NYSE:ALC) reports strong Q3 2023 financial results with $2.3 billion in sales, up 8%, or 9% constant currency. Diluted EPS increased by 78%, or up 97% cc, and core diluted EPS up by 32%, or 41% cc. Operating margin improved by 3.0 percentage points, and the company generated $937 million of cash from operating activities and $592 million of free cash flow in the first nine months of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.91%
Tags
earnings
-
News
Alcon Canada Launches Clareon Vivity, its Latest Advancement in Presbyopia Correcting IOLs
Rhea-AI Summary
Alcon: Clareon Vivity, the first non-diffractive EDOF IOL with X-WAVE Technology, is now available in Canada, offering high-quality vision and spectacle independence for cataract patients. Surgeons can now provide patients with a lens designed to deliver optimal outcomes, comparable to a monofocal IOL, while minimizing visual disturbances. The lens features X-WAVE technology and glistening-free material, offering excellent distance, intermediate, and functional near vision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.14%
Tags
none
News
Alcon Showcases Cloud-based Planning and World-class Digital Technologies During AAO 2023
Rhea-AI Summary
Alcon announces full U.S. commercial availability of cloud-based cataract planner, SMARTCataract, which offers seamless connectivity for surgical ophthalmic practices. The platform has demonstrated significant time savings during the cataract evaluation, planning process, operating room, and postoperative workflow. Alcon will showcase its digital offerings at the upcoming American Academy of Ophthalmology (AAO) 2023 annual meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
Stock ALC logo
Alcon Inc.

NYSE:ALC

ALC Rankings

#320 Ranked by Market Cap
#1066 Ranked by Stock Gains
#2051 Ranked by Dividends

ALC Stock Data

39.45B
492.28M
0.14%
66.11%
0.88%
Ophthalmic Goods Manufacturing
Manufacturing
Link
Switzerland
Vernier

About ALC

Alcon is an American Swiss medical company specializing in eye care products with headquarters in Geneva, Switzerland, and incorporated in Fribourg, Switzerland.